Uni-Bio Science Group Wins NMPA Nod for Generic Forteo Injection for Osteoporosis
Hong Kong-listed biopharmaceutical company Uni-Bio Science Group Ltd (HKG: 0690) has announced that it has...
NYSE: LLY
Alphabet’s Isomorphic Labs Inks Pharma Partnerships with Eli Lilly and Novartis
Isomorphic Labs, a drug discovery company under the umbrella of Google’s parent group Alphabet (NASDAQ:...
Eli Lilly Secures NMPA Approval for Emgality as Preventive Migraine Treatment in China
Eli Lilly (NYSE: LLY) has received marketing approval from the National Medical Products Administration (NMPA)...
Sanofi CEO Paul Hudson Rules Out GLP-1 Competition, Eyes Next-Gen Weight-Management Therapies
Paul Hudson, CEO of Sanofi (NASDAQ: SNY), stated this week that the France-based pharmaceutical company...
Eli Lilly Appoints First Female Leader for China Unit with Huzur Devletsah at the Helm
Eli Lilly and Company (NYSE: LLY), a leading pharmaceutical corporation in the U.S., has announced...
Innovent Biologics Initiates Phase III Trial for Mazdutide in Obesity Treatment
Innovent Biologics Inc., a biopharmaceutical company based in China (HKG: 1801), has announced the first...
Eli Lilly Teams Up with Fauna Bio to Uncover New Anti-Obesity Drug Targets
Eli Lilly (NYSE: LLY) has entered a collaboration agreement with fellow U.S. firm Fauna Bio...
Eli Lilly Completes Acquisition of Point Biopharma, Expanding Radiopharmaceutical Portfolio
Eli Lilly (NYSE: LLY) has finalized its acquisition of radiopharmaceutical company Point Biopharma (NASDAQ: PNT)...
BMS Expands Oncology Portfolio with $4.1 Billion RayzeBio Acquisition
Bristol Myers Squibb (BMS; NYSE: BMY) has announced the acquisition of RayzeBio (NASDAQ: RYZB), a...
Jiangsu Hengrui Pharmaceuticals Wins NMPA Approvals for SLE and Lymphoma Drug Candidates
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has announced that...
Organon In-Licenses Eli Lilly’s Emgality and Rayvow for European Migraine Market
Organon (NYSE: OGN), a specialist in women’s health, has in-licensed migraine treatments Emgality (galcanezumab) and...
Eli Lilly Seeks Approval for Pirtobrutinib in China for Relapsed Mantle Cell Lymphoma
Eli Lilly (NYSE: LLY) has submitted a marketing approval application for pirtobrutinib, an oral, non-covalent...
Roche Expands Beyond Oncology with USD 2.7 Billion Carmot Therapeutics Acquisition
Swiss pharmaceutical giant Roche (SWX: ROG) has entered into an agreement to acquire U.S. biotech...
Eli Lilly’s Jaypirca Receives FDA Accelerated Approval for Chronic Lymphocytic Leukemia
The US Food and Drug Administration (FDA) has granted Eli Lilly (NYSE: LLY) an accelerated...
Ambio Gains FDA Approval for Generic Forteo, Challenging Eli Lilly’s Osteoporosis Market
Ambio has secured regulatory approval from the U.S. Food and Drug Administration (FDA) for its...
Eli Lilly Partners with Prism BioLab to Discover Peptide-Mimicking Small Molecule Inhibitors
Eli Lilly and Company (NYSE: LLY) has entered into a partnership with Japan-based biotechnology firm...
Boehringer Ingelheim and Eli Lilly’s Jardiance Receives NMPA Approval for CKD Treatment
Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have announced that their SGLT2 inhibitor, Jardiance...
Boehringer Ingelheim and Eli Lilly Secure NMPA Approval for Jardiance in Chronic Kidney Disease
Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have announced the receipt of marketing approval...
Eli Lilly Clears Final Regulatory Hurdle with NRC Approval for Point Biopharma Acquisition
The Nuclear Regulatory Commission (NRC) of the US has given its approval for the transfer...
Eli Lilly’s Donanemab on Track for Priority Review in China for Early-Stage Alzheimer’s
The China’s Center for Drug Evaluation (CDE) website has indicated that Eli Lilly’s (NYSE: LLY)...